HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.

Abstract
Ranpirnase (Onconase) is the first ribonuclease to enter cancer clinical trials. In prior phase II trials, responses were seen in mesothelioma and other solid tumors. This phase II trial tested ranpirnase (480 microg/m2/w) in 14 patients with refractory advanced renal cell cancer. The median performance status was zero and the median age was 55. All patients had prior immunotherapy and three had prior chemotherapy. No responses were seen in 14 patients. The median survival from on study was 16 months (range two to 28 months). At this dose and schedule ranpirnase has minimal activity in metastatic renal cell cancer.
AuthorsN J Vogelzang, M Aklilu, W M Stadler, M C Dumas, S M Mikulski
JournalInvestigational new drugs (Invest New Drugs) Vol. 19 Issue 3 Pg. 255-60 ( 2001) ISSN: 0167-6997 [Print] United States
PMID11561684 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Ribonucleases
  • ranpirnase
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
  • Carcinoma, Renal Cell (drug therapy, mortality, secondary)
  • Female
  • Humans
  • Kidney Neoplasms (drug therapy, mortality, pathology)
  • Male
  • Middle Aged
  • Ribonucleases (administration & dosage, adverse effects, therapeutic use)
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: